ReviewZeitschrift fur Gerontologie und Geriatrie2017
[Parkinson's disease in the elderly].
Review in Zeitschrift fur Gerontologie und Geriatrie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Visual Perturbation Suggests Increased Effort to Maintain Balance in Early Stages of Parkinson's to be an Effect of Age Rather Than Disease.Frontiers in human neuroscience · 2022Article
- Drug safety profiles in geriatric patients with Parkinson's disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis.Journal of neural transmission (Vienna, Austria : 1996) · 2021Article
- Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.Drugs & aging · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the increasing life expectancy and a higher incidence in the elderly, the number of elderly patients with idiopathic Parkinson's disease will increase in the coming years. Since the burden of comorbidities is higher and medication side effects are more likely in the elderly, particularly in the light of frequently occurring polypharmacy, increased awareness and therapeutic knowledge is necessary. Besides the therapy of motor symptoms, non-motor symptoms, e. g. neuropsychiatric and autonomic disorders, also need to be addressed as they can also greatly impair the quality of life. In more advanced stages of the disease, non-pharmacological treatment, medical aids and caregiving become more important. A close integration in the social environment is of great importance for the implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.